The median survival of patients diagnosed with glioblastoma is 12–15 months, with a five-year survival rate of 5%, and cutaneous melanoma is responsible for 80% of deaths from dermatological cancer. Therefore, there is an urgent need to develop novel patient-adjusted anticancer immunotherapies that actively stimulate antitumor T cells, generate long- term memory, and result in significant clinical benefits. Dendritic cells (DCs) vaccines are used in cancer immunotherapy involving the use of DCs loaded with antigenic material derived from or based on the autologous tumor. In this project, we aim to develop and evaluate the use of novel and more efficient DC vaccines loaded with tumor lysates for melanoma and glioblastoma immunotherapy.